Targeting Diabetes Mellitus through Phytochemicals:

A Systematic Overview of Plant-Derived Bioactives, Pathophysiological Mechanisms and Clinical Implications

 

Mukund M. Pache¹*, Krushi H. Pradhan¹, Ashwini S. Thorat¹, Rohini R. Mule¹,

Sadanand D. Manoorkar¹, Avinash B. Darekar²

¹Department of Pharmacognosy, K.V.N. Naik S.P. Sanstha's,

Institute of Pharmaceutical Education and Research,          Nashik, 422002, Maharashtra, India.

²Principal, K.V.N. Naik S. P. Sanstha's,

Institute of Pharmaceutical Education & Research,          Nashik, 422002, Maharashtra, India.

 

ABSTRACT:

Diabetes mellitus (DM) is a severe metabolic disorder characterised by persistently high blood glucose levels, which arise due to inadequate insulin secretion, dysfunctional insulin activity, or a combination of these factors. While pharmacological treatments have advanced significantly, conventional therapies often fail to deliver optimal results due to their broad-spectrum approach. This challenge has led to growing interest in phytochemicals, naturally occurring bioactive compounds from plants, as alternative or complementary strategies for diabetes management. Various phytochemicals, including polyphenols, flavonoids, alkaloids, and terpenoids, have demonstrated notable antidiabetic properties. These compounds improve insulin sensitivity, promote better glucose regulation, reduce oxidative stress, and lower inflammation. Their mechanisms of action involve enhancing β-cell function, inhibiting α-glucosidase enzymes, and promoting lipid homeostasis. Evidence from both preclinical and clinical studies supports their therapeutic potential and safety profile. Nevertheless, further well-structured clinical trials are essential to establish appropriate dosages, long-term safety, and efficacy. This review emphasises the promising role of phytochemicals in diabetes management, underscoring their value in enhancing glycaemic control and mitigating complications.

 

 

 

INTRODUCTION:

Diabetes mellitus (DM) ranks globally among the most widespread metabolic disorders. As of 2021, approximately 537 million adults were diagnosed with this condition, and projections suggest this figure may surge to 783 million by 2045^1,2. Diabetes mellitus (DM) is generally categorised into three primary types: Type 1 diabetes (T1D), Type 2 diabetes (T2D), and gestational diabetes mellitus (GDM)³. Managing this condition remains a significant challenge for healthcare systems worldwide. Type 1 diabetes is an autoimmune condition distinguished by the complete absence of insulin production, while Type 2 diabetes arises from insulin resistance and inadequate insulin secretion. Gestational diabetes develops during pregnancy and may result in complications affecting both the mother and the child⁴. Chronic hyperglycaemia associated with Diabetes leads to both microvascular and macrovascular complications, ultimately resulting in a diminished quality of life and reduced life expectancy^5,6.

 

Current Challenges in Diabetes Management:

Traditional treatments for Diabetes, including dietary management, metformin, and insulin therapies, remain foundational to diabetes care. However, these treatments often come with a range of adverse effects from long-term use, such as hypoglycaemia, nausea, gastrointestinal distress, and weight gain. Additionally, they tend to manage symptoms rather than address the underlying causes of the disease⁷. The global healthcare burden is further exacerbated by issues such as patient non-compliance, high medication costs, and healthcare challenges in low-income countries, which can push individuals deeper into poverty. Therefore, it is crucial to explore alternative management strategies that are holistic, safe, and accessible for individuals dealing with Diabetes⁸.

 

Role of Phytochemicals:

Phytochemicals are natural compounds in plants that contribute to their colour, flavour, and resilience against environmental challenges. These compounds include alkaloids, phenolic acids, flavonoids, terpenes, and saponins⁹. An increasing body of evidence supports that these biologically active substances can exert anti-diabetic effects, suggesting their potential as complementary or alternative treatments. The beneficial effects of phytochemicals are partly attributed to their ability to enhance insulin sensitivity, modulate glucose metabolism, reduce oxidative stress, and improve lipid levels¹⁰. Furthermore, their bioavailability and excellent safety profile appeal to patients seeking a holistic and sustainable approach to health. This review explores the therapeutic potential of phytochemicals in diabetes management, including their mechanisms of action, preclinical and clinical evidence, and opportunities for integration into current treatment regimens. It aims to bridge ancient wisdom with modern scientific understanding, highlighting phytochemicals as a promising avenue in the fight against diabetes.

 

1.     Pathophysiology Of Diabetes Mellitus:

Diabetes mellitus is a consequence of a complex alteration in metabolism at the cellular level. Understanding the pathophysiology is crucial as it provides insight into who can be successfully targeted by phytochemicals.

1) Insulin Resistance: A hallmark of Type 2 diabetes is insulin resistance, wherein peripheral tissues such as skeletal muscle, adipose tissue, and the liver exhibit a diminished response to insulin. This impaired response reduces glucose uptake and promotes enhanced gluconeogenesis in the liver, ultimately contributing to elevated blood glucose levels (hyperglycaemia)¹¹. Several factors contribute to this condition, including diminished signalling from insulin receptors, the activation of stress kinases, and an abnormal lipid profile. Research indicates that phytochemicals, including mono- and polysaccharides, can enhance insulin sensitivity by modulating the PI3K/Akt signalling pathway and reducing free fatty acid levels, which otherwise disrupt insulin signalling^12,13.

 

2) Beta-Cell Function: The function and mass of pancreatic β-cells are crucial factors in the development of Diabetes. Excessive levels of glucose and fatty acids can trigger stress within the endoplasmic reticulum, and prolonged exposure to elevated blood concentrations of these substances leads to Diabetes stress. Furthermore, high levels of glucose and fatty acids, referred to as lipotoxicity, can result in β-cell death or apoptosis of islet cells¹⁴. Phytochemicals, particularly polyphenols like resveratrol, may offer protective benefits for β-cells by mitigating oxidative damage and enhancing insulin secretion, among other effects¹⁵.

 

3) Oxidative Stress: Oxidative stress plays a crucial role in developing Diabetes and its associated complications. An increase in reactive oxygen species (ROS) and other free radicals can lead to significant cellular damage, impairing their function over time¹⁶. Fortunately, phytochemicals derived from phenolic acids and flavonoids, known for their potent antioxidant properties, effectively address this issue. These compounds can neutralise free radicals and enhance the activity of endogenous antioxidant enzymes, such as superoxide dismutase (SOD), through the use of herbal extracts rich in these beneficial materials^17,18.

 

4) Chronic Inflammation: Chronic low-level inflammation significantly contributes to insulin resistance and β-cell failure. Inflammatory elements such as IL-1β, IL-6, and TNF-α in the islets disrupt insulin signal transduction pathways and exacerbate oxidative stress. For instance, certain alkaloids, like berberine, possess anti-inflammatory properties that can inhibit diabetes migration and reduce the release of specific cytokines. They aid in achieving metabolic goals by helping regulate energy levels, including maintaining stable blood sugar levels¹⁹.

 

Figure 1. Diagram showing the pathophysiology of the two primary forms of diabetic mellitus Physical Sluggishness and Fatness and physical sluggishness are strongly associated with the development of type 2 diabetes.²⁰

 

Phytochemicals provide a variety of effective prevention strategies for diabetes. However, diabetes is a complex disorder that involves multiple pathways, making it ineffective to focus solely on one or two mechanisms. The most effective approach to combating diabetes should target the condition comprehensively, addressing multiple aspects simultaneously. By adopting such a strategy, it may be possible to delay the gradual health decline associated with diabetes for several years. It is essential to remain vigilant, particularly during the early stages of diabetes, to enhance prevention and management efforts²⁰.

 

2.     Classification Of Phytochemicals:

Phytochemicals include many plants' bioactive compounds, each with unique functions or structures. They are sorted by structure and way of acting^21,22.

 

1) Flavonoids: Flavonoids are polyphenolic compounds renowned for their significant antioxidant, anti-inflammatory, and antidiabetic properties. These bioactive molecules can be categorised into various subclasses, including flavones, flavonols, and isoflavones. Notable examples include quercetin, which is found in onions and apples; kaempferol, present in green tea and broccoli; and catechins, abundant in green tea and cocoa²³. Flavonoids have shown promising effects in diabetes management by enhancing insulin sensitivity. This is accomplished by promoting GLUT4 translocation, which facilitates glucose uptake into cells, and the inhibition of α-glucosidase, an enzyme that contributes to postprandial glucose spikes.²⁴. Furthermore, flavonoids help reduce oxidative stress and inflammatory responses, thereby preserving the integrity and functionality of pancreatic β-cells, which is essential for effective glycaemic control²⁵.

 

2) Alkaloids: Alkaloids are nitrogen-containing organic compounds well-known for their therapeutic properties. Notable examples include berberine, derived from goldenseal and barberry, and capsaicin, commonly found in chilli peppers. Alkaloids have demonstrated considerable potential in the management of Diabetes. Berberine, in particular, has been thoroughly researched for its ability to lower glucose levels. Its mode of action is linked to the activation of AMP-activated protein kinase (AMPK), a key enzyme that promotes glucose uptake and regulates lipid metabolism²⁶. Conversely, capsaicin is known to influence insulin secretion and enhance insulin sensitivity, contributing to improved glycaemic control. These characteristics highlight the potential of alkaloids as valuable contributors to diabetes management strategies²⁷.

 

3) Terpenoids: Terpenoids, also called isoprenoids, are compounds derived from isoprene units and recognised for their diverse biological activities. Notable examples of terpenoids include limonene, which is found in citrus fruits; ginsenosides, present in ginseng; and curcumin, a primary component of turmeric. Terpenoids play a crucial role in diabetes management by modulating inflammatory pathways, improving lipid profiles, and enhancing antioxidant defences²⁸. Curcumin, in particular, has been shown to inhibit the activity of nuclear factor kappa B (NF-κB) and reduce oxidative stress, thereby promoting glucose metabolism. These mechanisms underscore the beneficial effects of terpenoids in maintaining metabolic balance and glycaemic control²⁹.

 

4) Polyphenols and Others: Polyphenols, including phenolic acids and stilbenes, are prevalent in various plant-based foods and exhibit considerable antidiabetic potential. Among them, resveratrol, found in grapes and red wine, and chlorogenic acid, present in coffee and blueberries, stand out. Research indicates that resveratrol enhances insulin sensitivity and protects pancreatic β-cells by activating sirtuins and reducing oxidative stress^30,31. Similarly, chlorogenic acid aids glycaemic control by slowing glucose absorption and positively influencing gut microbiota composition. These mechanisms collectively highlight the potential of polyphenols to serve as a complementary treatment along with diabetes therapies³².

 

By targeting multiple pathways involved in the pathogenesis of Diabetes, these phytochemicals present promising adjuncts to existing treatments. Ongoing research into their clinical applications is crucial for fully realising their therapeutic potential in improving diabetes management outcomes³³.

 

Table 1. Classification of Phytochemicals with Antidiabetic Properties

Class	Subtypes/Examples	Natural Sources	Mechanism of Antidiabetic Action
Flavonoids	Quercetin, Kaempferol	Apples, Green Tea	Antioxidant, ↑ GLUT4, α-glucosidase inhibition
Alkaloids	Berberine, Capsaicin	Barberry, Chilli	AMPK activation, ↑ Insulin secretion
Terpenoids	Curcumin, Ginsenosides	Turmeric, Ginseng	↓ NF-κB, ↑ Glycogen storage
Polyphenols	Resveratrol, Chlorogenic Acid	Grapes, Coffee	SIRT1 activation, Delayed glucose absorption

 

3.     Comprehensive Mechanisms of Action of Phytochemicals in Diabetes Management:

Phytochemical agents achieve their antidiabetic effects by targeting the root causes and complications of diabetes. Their mechanisms of action include antioxidant and anti-inflammatory activities, regulation of glucose metabolism, and protection of pancreatic β-cells. By acting through these interconnected pathways, phytochemical agents offer extensive therapeutic potential for effectively managing diabetes³⁴.

 

1) Antioxidant Properties: Oxidative stress plays a pivotal role in the development and progression of diabetes and its related complications. This condition stems from excessive reactive oxygen species (ROS) production combined with compromised antioxidant defences, leading to cellular damage involving lipids, proteins, and DNA. Such damage worsens insulin resistance and impairs β-cell functionality. Phytochemicals, recognised for their potent antioxidant effects, can counteract oxidative stress by scavenging free radicals, enhancing the activity of endogenous antioxidant enzymes, and reducing oxidative injury^17,18.

 

From a mechanistic perspective, flavonoids such as quercetin and catechins combat ROS through their hydroxyl groups. Additionally, these compounds stimulate the expression of antioxidant enzymes, including superoxide dismutase (SOD), catalase, and glutathione peroxidase, via the activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) signalling pathway. Curcumin, a polyphenolic compound derived from Diabetes, demonstrates significant ROS-scavenging abilities and activates Nrf2, thereby reducing Diabetes stress in pancreatic β-cells and improving glucose tolerance in animal models³⁵. Additionally, resveratrol in grapes and red wine decreases oxidative stress markers like malondialdehyde (MDA) and enhances insulin sensitivity in clinical trials. By mitigating oxidative stress, these phytochemicals help maintain insulin sensitivity and β-cell function, ultimately slowing the progression of Diabetes³⁶.

 

2) Anti-Inflammatory Effects: Chronic low-grade inflammation is a key characteristic of diabetes, driven largely by pro-inflammatory cytokines such as tumour necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β). These cytokines play a pivotal role in promoting inflammatory responses that contribute to the progression of the disease. These cytokines compromise insulin signalling, elevate oxidative stress, and promote β-cell apoptosis. Phytochemicals have shown great promise in modulating inflammatory pathways, effectively reducing cytokine production and activity³⁷.

 

Alkaloids like berberine demonstrate anti-inflammatory properties by suppressing the nuclear factor-kappa B (NF-κB) signalling pathway, a crucial regulator of inflammation, which in turn reduces cytokine production³⁸. Likewise, flavonoids such as kaempferol help decrease TNF-α and IL-6 levels by modulating the mitogen-activated protein kinase (MAPK) and Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathways³⁹. Similarly, curcumin inhibits NF-κB activation and reduces inflammatory markers in diabetic patients, leading to improved metabolic outcomes⁴⁰. Additionally, resveratrol has decreased systemic inflammation by lowering high-sensitivity C-reactive protein (hs-CRP) levels in individuals with Diabetes. Through these anti-inflammatory mechanisms, phytochemicals help alleviate insulin resistance and protect against diabetes-related complications³⁶.

 

3) Glucose Metabolism Regulation: Phytochemicals significantly impact glucose metabolism through multiple mechanisms, such as stimulating insulin secretion, enhancing insulin sensitivity, reducing glucose absorption, and facilitating glycogen storage⁴¹.

 

a) Enhancing Insulin Secretion: Phytochemicals help protect pancreatic β-cells from damage and stimulate insulin release. For instance, epicatechin found in cocoa enhances calcium influx into β-cells, thereby boosting insulin secretion⁴².

 

b) Improving Insulin Sensitivity: Phytochemicals modulate the signalling pathways of insulin receptors, improving glucose uptake in peripheral tissues. Berberine, for example, activates AMP-activated protein kinase (AMPK), a crucial regulator of cellular energy balance, thus enhancing glucose uptake and lipid metabolism⁴³.

 

c) Inhibiting Glucose Absorption: Certain phytochemicals inhibit carbohydrate-digesting enzymes such as α-glucosidase and α-amylase, reducing postprandial glucose spikes. For example, chlorogenic acid from coffee inhibits intestinal glucose absorption, contributing to improved glycaemic control⁴⁴.

 

d) Promoting Glycogen Storage: Some terpenoids enhance glycogen synthesis by activating synthase enzymes. Ginsenosides from ginseng, for instance, improve hepatic glycogen storage and diminish gluconeogenesis. These diverse effects underscore the essential role of phytochemicals in managing the dysregulated glucose metabolism often associated with Diabetes⁴⁵.

4) Beta-Cell Protection: Pancreatic β-cell dysfunction and apoptosis are central to diabetes progression, particularly in Type 2 diabetes. Phytochemicals offer protective effects by mitigating glucotoxicity, lipotoxicity, oxidative stress, and inflammation⁴⁶.

 

a) Mitigating Apoptosis: Phytochemicals reduce apoptosis by modulating pro-apoptotic and anti-apoptotic pathways. For example, resveratrol activates sirtuins (SIRT1), suppressing pro-apoptotic proteins such as Bax and upregulating anti-apoptotic proteins like Bcl-2, thereby protecting β-cell viability⁴⁷.

 

b) Promoting Regeneration: Certain compounds stimulate β-cell proliferation and neogenesis. Curcumin, for instance, enhances β-cell regeneration by modulating growth factors such as pancreatic duodenal homeobox 1 (PDX1)^48,49.

 

c) Clinical Evidence: Polyphenols like epigallocatechin gallate (EGCG) from green tea reduce oxidative stress-induced β-cell damage, preserving insulin secretion. By safeguarding β-cell health and function, phytochemicals contribute to sustained glycaemic control and delay diabetes progression^50,51.

 

The diverse mechanisms of action of phytochemicals, including their antioxidant and anti-inflammatory effects, regulation of glucose metabolism, and β-cell protection, make them promising candidates for diabetes management. Continued research into their molecular pathways and rigorous clinical validation will pave the way for their integration into therapeutic strategies.

 

4.     Evidence From Studies:

The potential of phytochemicals in managing diabetes mellitus has been widely investigated through in vitro, in vivo, and clinical studies. These studies provide mechanistic insights, preclinical validation, and evidence of safety and efficacy in human populations.

 

1) In Vitro Studies: In vitro studies using cell lines and isolated tissues offer fundamental insights into the molecular mechanisms by which phytochemicals exert antidiabetic effects^52,53.

 

a) Mechanistic Insights: Curcumin has demonstrated protective effects in β-cell line studies by reducing oxidative stress-induced apoptosis. This protective effect is mediated by the activation of nuclear factor erythroid 2-related factor 2 (Nrf2) and the inhibition of nuclear factor-kappa B (NF-κB) activity, which helps shield β-cells from oxidative damage and inflammation^54,55. Resveratrol enhances glucose uptake in hepatocytes and adipocytes by stimulating AMP-activated protein kinase (AMPK) and facilitating GLUT4 translocation⁵⁶. Likewise, berberine enhances glucose uptake in L6 myotubes via AMPK activation, mimicking the physiological effects of exercise⁵⁷.

 

b) Enzyme Inhibition: Phytochemicals such as catechins and chlorogenic acid inhibit carbohydrate-digesting enzymes like α-glucosidase and α-amylase in cell-free assays, reducing glucose absorption in the intestine⁵⁸.

 

c) Anti-Inflammatory Effects: Kaempferol, studied in macrophage cell lines, has been found to reduce inflammatory cytokine production, mitigating insulin resistance⁵⁹.

 

These in vitro findings provide a mechanistic basis for the observed antidiabetic effects of phytochemicals, guiding further in vivo and clinical studies.

 

2) In Vivo Studies: Animal models, including diabetic mice, rats, and zebrafish, offer crucial insights into the systemic effects of phytochemicals on glucose metabolism and diabetes-related complications⁶⁰.

 

a) Curcumin: In diabetic rats induced with streptozotocin (STZ), curcumin supplementation notably lowered fasting blood glucose levels and improved insulin sensitivity. Additionally, it enhanced pancreatic β-cell function by mitigating oxidative stress and inflammation, as indicated by reduced malondialdehyde (MDA) levels and elevated superoxide dismutase (SOD) activity^61,62.

 

b) Resveratrol: Resveratrol has demonstrated antidiabetic effects in db/db mice, improving insulin sensitivity and reducing hepatic glucose production through sirtuin (SIRT1) activation. Resveratrol also reduced oxidative stress and ameliorated complications such as nephropathy^63,64.

 

c) Berberine: In high-fat diet-induced diabetic rats, berberine improved glucose tolerance and lipid profiles by modulating gut microbiota composition. Enhanced glucagon-like peptide-1 (GLP-1) secretion contributed to improved glycaemic control⁶³.

 

d) Catechins: Green tea catechins have been shown to lower blood glucose levels in STZ-induced diabetic mice by reducing intestinal glucose absorption and improving insulin sensitivity in peripheral tissues⁶³.

 

e) Multi-Target Effects: Phytochemicals like ginsenosides from ginseng have improved glucose metabolism and β-cell regeneration, underscoring their systemic impact⁶⁵.

 

While in vivo studies confirm the efficacy of phytochemicals, variability in dosages, formulations, and models highlights the need for standardisation and translational research.

3) Clinical Studies: Clinical trials provide robust evidence of phytochemical safety and efficacy in human populations.

 

a) Curcumin: A randomised, double-blind, placebo-controlled study investigated the effects of curcumin in individuals with prediabetes. Participants who received curcumin supplementation (1 g/day for 9 months) experienced a significantly lower progression rate to Type 2 diabetes compared to the placebo group (0% vs. 16.4%). The study also reported notable improvements in insulin sensitivity, β-cell function, and reductions in inflammatory markers such as TNF-α and IL-6^65,66.

 

b) Resveratrol: A meta-analysis of resveratrol supplementation in diabetic patients showed improved glycaemic control. Doses ranging from 250 mg to 1 g/day reduced fasting blood glucose, HbA1c, and insulin resistance. Resveratrol's activation of SIRT1 and enhancement of mitochondrial function contributed to these outcomes^67,68.

 

c) Berberine: In a comparative clinical trial, berberine (500 mg thrice daily) was as effective as metformin in reducing fasting plasma glucose, postprandial glucose, and HbA1c levels in newly diagnosed Type 2 diabetes patients. Berberine also improved lipid profiles and was well-tolerated, with mild gastrointestinal side effects^69,70.

 

d) Epigallocatechin Gallate (EGCG): Epigallocatechin gallate (EGCG), a prominent compound in green tea, has been investigated for its glucose-lowering properties. Studies in overweight and obese individuals with prediabetes have shown that EGCG supplementation improves fasting glucose levels, enhances insulin sensitivity, and decreases oxidative stress markers^50,70.

 

e) Chlorogenic Acid: Chlorogenic acid from coffee has been shown to improve glucose metabolism. A study in individuals with mild hyperglycaemia demonstrated reduced postprandial glucose spikes following chlorogenic acid supplementation⁷¹.

 

4) Challenges in Clinical Studies:^72–74

a) Variability in Results: Differences in dosages, formulations, and study designs often result in inconsistent outcomes.

 

b) Safety and Tolerability: While phytochemicals are generally safe, some individuals experience mild gastrointestinal discomfort or potential herb-drug interactions, requiring further investigation.

 

c) Long-Term Efficacy: Most studies are short-term, underscoring the need for extended trials to assess sustained benefits and safety.

 

Evidence from in vitro, in vivo, and clinical studies highlights the therapeutic potential of phytochemicals in diabetes management. Mechanistic studies demonstrate their ability to target oxidative stress, inflammation, glucose metabolism, and β-cell function⁷⁴. Animal models confirm their systemic efficacy, while clinical trials validate their safety and efficacy in human populations. Future research should prioritise standardising dosages, optimising formulations, and conducting long-term trials to realise phytochemicals' potential as complementary therapies for Diabetes fully⁷⁵.

 

Table 2. Summary of In Vitro, In Vivo, and Clinical Findings

Phytochemical	Study Type	Key Findings	References
Curcumin	Clinical	Reduced DM incidence in prediabetics	64
Resveratrol	In Vivo	Improved insulin sensitivity via SIRT1	61
Berberine	Clinical	Comparable to metformin in glycaemic control	67
EGCG	Clinical	↓ Fasting glucose and oxidative stress	48
Chlorogenic Acid	In Vitro	Inhibited α-glucosidase; ↓ postprandial glucose	69

 

5.     Synergistic Effects:

The combined use of various phytochemicals presents enhanced therapeutic efficacy through synergistic mechanisms. This strategy takes advantage of the complementary actions of different compounds, allowing them to target multiple aspects of Diabetes pathophysiology simultaneously. For example, combinations of polyphenols and flavonoids can amplify antioxidant effects. At the same time, alkaloids and terpenoids improve glucose metabolism and insulin sensitivity⁷⁶.

 

Examples of Synergy: In vitro studies have shown that combining quercetin and resveratrol results in superior antioxidant and anti-inflammatory effects compared to each treatment alone. Similarly, pairing curcumin with berberine enhances AMPK activation, improving glucose uptake and lipid metabolism in animal models^77,78.

 

Interaction with Conventional Therapies: Phytochemicals also show promise as adjuncts to conventional diabetes treatments. For instance, the combination of berberine and metformin has demonstrated better glycaemic control than either treatment administered separately. Moreover, phytochemicals may help alleviate the side effects of synthetic drugs, such as gastrointestinal discomfort or hypoglycaemia, by improving metabolic balance and reducing oxidative stress^21,33.

 

These synergistic effects emphasise the potential of integrating phytochemicals with existing therapies for a more comprehensive approach to diabetes management. Nonetheless, further research is necessary to optimise these combinations and evaluate their safety profiles.

 

6.     Challenges and Limitations:

Despite their potential, phytochemicals encounter several challenges in clinical applications:

1)    Bioavailability: Many phytochemicals, such as curcumin and resveratrol, exhibit poor bioavailability due to rapid metabolism and limited absorption. This significantly constrains their therapeutic efficacy in humans⁷⁹.

2)    Variability in Composition: Natural variations in plant sources, cultivation conditions, and extraction methods result in inconsistencies in the composition and potency of phytochemical preparations⁸⁰.

3)    Lack of Standardisation: The absence of standardised dosing and formulations complicates the comparison of study outcomes and hinders the development of clinical guidelines⁸¹.

4)    Limited Large-Scale Studies: Most clinical trials involving phytochemicals are small-scale, short-term, and lack rigorous designs, restricting their acceptance as mainstream therapeutic agents²¹.

5)    Herb-Drug Interactions: The potential for interactions between phytochemicals and conventional medications raises safety concerns, particularly in cases of polypharmacy, which is common among diabetic patients⁸².

 

Table 3. Challenges and Limitations of Phytochemicals in Diabetes Management

Challenge	Description	Potential Solutions
Poor bioavailability	Rapid metabolism, low absorption	Nanoformulations, liposomes
Variability	Differences in plant origin and preparation	Standardisation of extracts
Herb-drug interaction	Risk in polypharmacy settings	Pharmacovigilance, patient education
Lack of large trials	Limited robust clinical evidence	Long-term RCTs with large sample sizes

 

Addressing these challenges through advanced formulations, standardised protocols, and large-scale clinical trials is crucial for unlocking the full potential of phytochemicals in diabetes care.

 

7.     Future Directions

The future of phytochemical research in diabetes management is poised for significant advancement through innovative strategies that enhance their efficacy and applicability:

1)    Advancements in Drug Delivery: The development of novel delivery systems—such as nanoparticles, liposomes, and hydrogels can significantly improve phytochemicals' bioavailability and targeted delivery. For example, curcumin-loaded nanoparticles have enhanced stability and therapeutic efficacy in preclinical studies^83,84.

 

2)    Personalised Medicine: Integrating genomic and metabolomic approaches can facilitate customising phytochemical-based interventions for individual patients. Identifying genetic polymorphisms influencing phytochemical metabolism or insulin sensitivity can guide treatment strategies^85–87.

 

3)    Combination Therapies: Investigating synergistic combinations of phytochemicals with conventional drugs or other natural compounds could maximise therapeutic outcomes⁸⁸.

 

4)    Focus on Prevention: Research should also explore the potential role of phytochemicals in preventing the onset of Diabetes, particularly among high-risk populations²⁰.

 

5)    Long-Term Studies: There is a pressing need for large-scale, longitudinal clinical trials to establish phytochemicals' safety, efficacy, and cost-effectiveness in diabetes management^20,89.

 

These advancements will bridge the divide between traditional knowledge and modern medicine, paving the way for phytochemicals to become vital to diabetes care.

 

CONCLUSION:

Phytochemicals offer a promising approach to managing diabetes mellitus by targeting key pathophysiological processes, including oxidative stress, inflammation, and β-cell dysfunction. Their natural origin, diverse range of bioactivities, and potential to complement conventional therapies underscore their significance in comprehensive diabetes care.

 

However, challenges such as poor bioavailability, inconsistent composition, and a lack of extensive clinical data impede their broader clinical application. To address these issues, future research should focus on developing enhanced formulations, standardised treatment protocols, and robust clinical trials to validate their efficacy and safety. Additionally, advancements in personalised medicine and innovative drug delivery systems present considerable opportunities to improve phytochemicals' bioavailability and therapeutic outcomes.

 

By integrating traditional knowledge with contemporary scientific advancements, phytochemicals could provide a sustainable, effective, and accessible solution for diabetes management. With ongoing exploration and refinement, these bioactive compounds may play a transformative role in enhancing glycaemic control and mitigating diabetes-related complications.

 

REFERENCES:

1.      Lin X, Xu Y, Pan X, et al. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep. 2020; 10(1): 14790; doi: 10.1038/s41598-020-71908-9.

2.      Ye J, Wu Y, Yang S, et al. The global, regional and national burden of type 2 diabetes mellitus in the past, present and future: a systematic analysis of the Global Burden of Disease Study 2019. Front Endocrinol. 2023; 14: 1192629; doi: 10.3389/fendo.2023.1192629.

3.      Auvinen A-M, Luiro K, Jokelainen J, et al. Type 1 and type 2 diabetes after gestational diabetes: a 23 year cohort study. Diabetologia. 2020; 63(10): 2123–2128; doi: 10.1007/s00125-020-05215-3.

4.      Mukerji G, Bacon S, Feig DS. Gestational Diabetes and Type 2 Diabetes During Pregnancy. In: Maternal-Fetal and Neonatal Endocrinology Elsevier; 2020; pp. 371–388; doi: 10.1016/B978-0-12-814823-5.00022-2.

5.      Stehouwer CDA. Microvascular Dysfunction and Hyperglycemia: A Vicious Cycle With Widespread Consequences. Diabetes. 2018; 67(9): 1729–1741; doi: 10.2337/dbi17-0044.

6.      Pache MM, Pangavhane RR. Immunotherapy in Autoimmune Diseases: Current Advances and Future Directions. Asian Journal of Pharmaceutical Research. 2025; 15(2): 183–191; doi: 10.52711/2231-5691.2025.00030.

7.      Tan SY, Mei Wong JL, Sim YJ, et al. Type 1 and 2 diabetes mellitus: A review on current treatment approach and gene therapy as potential intervention. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2019; 13(1): 364–372; doi: 10.1016/j.dsx.2018.10.008.

8.      Karachaliou F, Simatos G, Simatou A. The Challenges in the Development of Diabetes Prevention and Care Models in Low-Income Settings. Front Endocrinol. 2020; 11: 518; doi: 10.3389/fendo.2020.00518.

9.      Huang W, Wang Y, Tian W, et al. Biosynthesis Investigations of Terpenoid, Alkaloid, and Flavonoid Antimicrobial Agents Derived from Medicinal Plants. Antibiotics. 2022; 11(10): 1380; doi: 10.3390/antibiotics11101380.

10.   Ahangarpour A, Sayahi M, Sayahi M. The antidiabetic and antioxidant properties of some phenolic phytochemicals: A review study. Diabetes & Metabolic Syndrome: Clinical Research & Reviews.  2019; 13(1): 854–857; doi: 10.1016/j.dsx.2018.11.051.

11.   Lee S-H, Park S-Y, Choi CS. Insulin Resistance: From Mechanisms to Therapeutic Strategies. Diabetes Metab J. 2022; 46(1): 15–37; doi: 10.4093/dmj.2021.0280.

12.   Rosenzweig T, Sampson SR. Activation of Insulin Signaling by Botanical Products. IJMS. 2021; 22(8): 4193; doi: 10.3390/ijms22084193.

13.   Pache M, Nikam S. Antibiotic Resistance: Current Challenges and Future Directions. Int J of Pharm Sci. 2025; 3(1): 1600–1622; doi: 10.5281/ZENODO.14690670.

14.   Eizirik DL, Pasquali L, Cnop M. Pancreatic β-cells in type 1 and type 2 diabetes mellitus: different pathways to failure. Nat Rev Endocrinol. 2020; 16(7): 349–362; doi: 10.1038/s41574-020-0355-7.

15.   Luo G, Xiao L, Wang D, et al. Resveratrol attenuates excessive ethanol exposure-induced β-cell senescence in rats: A critical role for the NAD+/SIRT1-p38MAPK/p16 pathway. The Journal of Nutritional Biochemistry. 2021; 89: 108568; doi: 10.1016/j.jnutbio.2020.108568.

16.   Ighodaro OM. Molecular pathways associated with oxidative stress in diabetes mellitus. Biomedicine & Pharmacotherapy. 2018; 108: 656–662; doi: 10.1016/j.biopha.2018.09.058.

17.   Zhang P, Li T, Wu X, et al. Oxidative stress and diabetes: antioxidative strategies. Front Med. 2020; 14(5): 583–600; doi: 10.1007/s11684-019-0729-1.

18.   Singh A, Kukreti R, Saso L, et al. Mechanistic Insight into Oxidative Stress-Triggered Signaling Pathways and Type 2 Diabetes. Molecules. 2022; 27(3): 950; doi: 10.3390/molecules27030950.

19.   Gong M, Duan H, Wu F, et al. Berberine Alleviates Insulin Resistance and Inflammation via Inhibiting the LTB4–BLT1 Axis. Front Pharmacol. 2021; 12: 722360; doi: 10.3389/fphar.2021.722360.

20.   Jin Y, Arroo R. The protective effects of flavonoids and carotenoids against diabetic complications—A review of in vivo evidence. Front Nutr. 2023; 10: 1020950; doi: 10.3389/fnut.2023.1020950.

21.   Alam S, Sarker MdMR, Sultana TN, et al. Antidiabetic Phytochemicals From Medicinal Plants: Prospective Candidates for New Drug Discovery and Development. Front Endocrinol. 2022; 13: 800714; doi: 10.3389/fendo.2022.800714.

22.   Pangavhane R, Pache M. Phytochemicals in The Management of Diabetes Mellitus:  A Comprehensive Review. Int J Sci R Tech. 2025; 2(4): 6–14; doi: 10.5281/zenodo.15122232.

23.   Shamsudin NF, Ahmed QU, Mahmood S, et al. Flavonoids as Antidiabetic and Anti-Inflammatory Agents: A Review on Structural Activity Relationship-Based Studies and Meta-Analysis. IJMS. 2022; 23(20): 12605; doi: 10.3390/ijms232012605.

24.   Proença C, Ribeiro D, Freitas M, et al. Flavonoids as potential agents in the management of type 2 diabetes through the modulation of α-amylase and α-glucosidase activity: a review. Critical Reviews in Food Science and Nutrition. 2022; 62(12): 3137–3207; doi: 10.1080/10408398.2020.1862755.

25.   Hussain T, Tan B, Murtaza G, et al. Flavonoids and type 2 diabetes: Evidence of efficacy in clinical and animal studies and delivery strategies to enhance their therapeutic efficacy. Pharmacological Research. 2020; 152: 104629; doi: 10.1016/j.phrs.2020.104629.

26.   Pache MM, Thorat AS, Mule RR, et al. Recent advances in the use of alkaloids as therapeutic agents: A pharmacognostic perspective. World Journal of Pharmaceutical Research. 2025; 14(2): 538–552.

27.   Rasouli H, Yarani R, Pociot F, et al. Anti-diabetic potential of plant alkaloids: Revisiting current findings and future perspectives. Pharmacological Research. 2020; 155: 104723; doi: 10.1016/j.phrs.2020.104723.

28.   Song B-R, Alam MB, Lee S-H. Terpenoid-Rich Extract of Dillenia indica L. Bark Displays Antidiabetic Action in Insulin-Resistant C2C12 Cells and STZ-Induced Diabetic Mice by Attenuation of Oxidative Stress. Antioxidants. 2022; 11(7): 1227; doi: 10.3390/antiox11071227.

29.   Huang J, Yi Q, You Y, et al. Curcumin suppresses oxidative stress via regulation of ROS/NF-κB signaling pathway to protect retinal vascular endothelial cell in diabetic retinopathy. Mol Cell Toxicol. 2021; 17(3): 367–376; doi: 10.1007/s13273-021-00144-7.

30.   Huang D-D, Shi G, Jiang Y, et al. A review on the potential of Resveratrol in prevention and therapy of diabetes and diabetic complications. Biomedicine & Pharmacotherapy. 2020; 125: 109767; doi: 10.1016/j.biopha.2019.109767.

31.   Sun C, Zhao C, Guven EC, et al. Dietary polyphenols as antidiabetic agents: Advances and opportunities. Food Frontiers. 2020; 1(1): 18–44; doi: 10.1002/fft2.15.

32.   Chen L, Teng H, Cao H. Chlorogenic acid and caffeic acid from Sonchus oleraceus Linn synergistically attenuate insulin resistance and modulate glucose uptake in HepG2 cells. Food and Chemical Toxicology. 2019; 127: 182–187; doi: 10.1016/j.fct.2019.03.038.

33.   Kong M, Xie K, Lv M, et al. Anti-inflammatory phytochemicals for the treatment of diabetes and its complications: Lessons learned and future promise. Biomedicine & Pharmacotherapy. 2021; 133: 110975; doi: 10.1016/j.biopha.2020.110975.

34.   Ansari P, Akther S, Hannan JMA, et al. Pharmacologically Active Phytomolecules Isolated from Traditional Antidiabetic Plants and Their Therapeutic Role for the Management of Diabetes Mellitus. Molecules. 2022; 27(13): 4278; doi: 10.3390/molecules27134278.

35.   Ghareghomi S, Rahban M, Moosavi-Movahedi Z, et al. The Potential Role of Curcumin in Modulating the Master Antioxidant Pathway in Diabetic Hypoxia-Induced Complications. Molecules. 2021; 26(24): 7658; doi: 10.3390/molecules26247658.

36.   Barber TM, Kabisch S, Randeva HS, et al. Implications of Resveratrol in Obesity and Insulin Resistance: A State-of-the-Art Review. Nutrients. 2022; 14(14): 2870; doi: 10.3390/nu14142870.

37.   Zatterale F, Longo M, Naderi J, et al. Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes. Front Physiol. 2020; 10: 1607; doi: 10.3389/fphys.2019.01607.

38.   Zhu Z, Xueying L, Chunlin L, et al. Effect of berberine on LPS-induced expression of NF- κ B/MAPK signalling pathway and related inflammatory cytokines in porcine intestinal epithelial cells. Innate Immun. 2020; 26(7): 627–634; doi: 10.1177/1753425920930074.

39.   Wu H, Lin X, Yang X, et al. Kaempferol attenuates inflammation in lipopolysaccharide‐induced gallbladder epithelial cells by inhibiting the MAPK / NF‐ΚB signaling pathway. Chem Biol Drug Des. 2024; 103(4): e14519; doi: 10.1111/cbdd.14519.

40.   Zamanian MY, Alsaab HO, Golmohammadi M, et al. NF‐κB pathway as a molecular target for curcumin in diabetes mellitus treatment: Focusing on oxidative stress and inflammation. Cell Biochemistry; Function. 2024; 42(4): e4030; doi: 10.1002/cbf.4030.

41.   Sayem A, Arya A, Karimian H, et al. Action of Phytochemicals on Insulin Signaling Pathways Accelerating Glucose Transporter (GLUT4) Protein Translocation. Molecules. 2018; 23(2): 258; doi: 10.3390/molecules23020258.

42.   Semwal DK, Kumar A, Aswal S, et al. Protective and therapeutic effects of natural products against diabetes mellitus via regenerating pancreatic β ‐cells and restoring their dysfunction. Phytotherapy Research. 2021; 35(3): 1218–1229; doi: 10.1002/ptr.6885.

43.   Li Y, Wang B, Shen J, et al. Berberine attenuates fructose-induced insulin resistance by stimulating the hepatic LKB1/AMPK/PGC1α pathway in mice. Pharmaceutical Biology. 2020; 58(1): 385–392; doi: 10.1080/13880209.2020.1756349.

44.   Kashtoh H, Baek K-H. Recent Updates on Phytoconstituent Alpha-Glucosidase Inhibitors: An Approach towards the Treatment of Type Two Diabetes. Plants. 2022; 11(20): 2722; doi: 10.3390/plants11202722.

45.   Jeong Y-J, Hwang M-J, Hong C-O, et al. Anti-hyperglycemic and hypolipidemic effects of black ginseng extract containing increased Rh4, Rg5, and Rk1 content in muscle and liver of type 2 diabetic db/db mice. Food Sci Biotechnol. 2020; 29(8): 1101–1112; doi: 10.1007/s10068-020-00753-3.

46.   Šrámek J, Němcová-Fürstová V, Kovář J. Molecular Mechanisms of Apoptosis Induction and Its Regulation by Fatty Acids in Pancreatic β-Cells. IJMS. 2021; 22(8): 4285; doi: 10.3390/ijms22084285.

47.   Wang P, Huang C, Gao J, et al. Resveratrol induces SIRT1-Dependent autophagy to prevent H2O2-Induced oxidative stress and apoptosis in HTR8/SVneo cells. Placenta. 2020; 91: 11–18; doi: 10.1016/j.placenta.2020.01.002.

48.   Yao X, Li K, Liang C, et al. Tectorigenin enhances PDX1 expression and protects pancreatic β-cells by activating ERK and reducing ER stress. Journal of Biological Chemistry. 2020; 295(37): 12975–12992; doi: 10.1074/jbc.RA120.012849.

49.   Srivastava NS, Srivastava RAK. Curcumin and quercetin synergistically inhibit cancer cell proliferation in multiple cancer cells and modulate Wnt/β-catenin signaling and apoptotic pathways in A375 cells. Phytomedicine. 2019; 52: 117–128; doi: 10.1016/j.phymed.2018.09.224.

50.   Mokra D, Joskova M, Mokry J. Therapeutic Effects of Green Tea Polyphenol (‒)-Epigallocatechin-3-Gallate (EGCG) in Relation to Molecular Pathways Controlling Inflammation, Oxidative Stress, and Apoptosis. IJMS. 2022; 24(1): 340; doi: 10.3390/ijms24010340.

51.   Jang H-J, Ridgeway SD, Kim J. Effects of the green tea polyphenol epigallocatechin-3-gallate on high-fat diet-induced insulin resistance and endothelial dysfunction. American Journal of Physiology-Endocrinology and Metabolism. 2013; 305(12): E1444–E1451; doi: 10.1152/ajpendo.00434.2013.

52.   Nie T, Cooper GJS. Mechanisms Underlying the Antidiabetic Activities of Polyphenolic Compounds: A Review. Front Pharmacol. 2021; 12: 798329; doi: 10.3389/fphar.2021.798329.

53.   Sharma P, Joshi T, Mathpal S, et al. In silico identification of antidiabetic target for phytochemicals of A. marmelos and mechanistic insights by molecular dynamics simulations. Journal of Biomolecular Structure and Dynamics. 2022; 40(21): 10543–10560; doi: 10.1080/07391102.2021.1944910.

54.   Daverey A, Agrawal SK. Curcumin Protects against White Matter Injury through NF-κB and Nrf2 Cross Talk. Journal of Neurotrauma. 2020; 37(10): 1255–1265; doi: 10.1089/neu.2019.6749.

55.   Lin X, Bai D, Wei Z, et al. Curcumin attenuates oxidative stress in RAW264.7 cells by increasing the activity of antioxidant enzymes and activating the Nrf2-Keap1 pathway. Mukhopadhyay P. ed. PLoS ONE. 2019; 14(5): e0216711; doi: 10.1371/journal.pone.0216711.

56.   Lu C, Xing H, Yang L, et al. Resveratrol Ameliorates High-Fat-Diet-Induced Abnormalities in Hepatic Glucose Metabolism in Mice via the AMP-Activated Protein Kinase Pathway. Zaid H. ed. Evidence-Based Complementary and Alternative Medicine. 2021; 2021: 1–9; doi: 10.1155/2021/6616906.

57.   Li W, Li D, Kuang H, et al. Berberine increases glucose uptake and intracellular ROS levels by promoting Sirtuin 3 ubiquitination. Biomedicine & Pharmacotherapy. 2020; 121: 109563; doi: 10.1016/j.biopha.2019.109563.

58.   Pérez-Nájera VC, Gutiérrez-Uribe JA, Antunes-Ricardo M, et al. Smilax aristolochiifolia Root Extract and Its Compounds Chlorogenic Acid and Astilbin Inhibit the Activity of α ‐Amylase and α ‐Glucosidase Enzymes. Tomczyk M. ed. Evidence-Based Complementary and Alternative Medicine. 2018; 2018(1): 6247306; doi: 10.1155/2018/6247306.

59.   Zhai H, Wang D, Wang Y, et al. Kaempferol alleviates adipose tissue inflammation and insulin resistance in db/db mice by inhibiting the STING/NLRP3 signaling pathway. Endocrine Connections 2024;13(5):e230379; doi: 10.1530/EC-23-0379.

60.   Asrafuzzaman Md, Cao Y, Afroz R, et al. Animal models for assessing the impact of natural products on the aetiology and metabolic pathophysiology of Type 2 diabetes. Biomedicine & Pharmacotherapy. 2017; 89: 1242–1251; doi: 10.1016/j.biopha.2017.03.010.

61.   Febriza A, Zahrah A, Andini N, et al. Potential Effect of Curcumin in Lowering Blood Glucose Level in Streptozotocin-Induced Diabetic Rats. DMSO. 2024; 17: 3305–3313; doi: 10.2147/DMSO.S468059.

62.   Sayeli VK, Shenoy AK. Antidiabetic effect of bio-enhanced preparation of turmeric in streptozotocin-nicotinamide induced type 2 diabetic Wistar rats. Journal of Ayurveda and Integrative Medicine. 2021; 12(3): 474–479; doi: 10.1016/j.jaim.2021.04.010.

63.   Yan H, Zhang Y, Lin X, et al. Resveratrol improves diabetic kidney disease by modulating the gut microbiota-short chain fatty acids axis in db/db mice. International Journal of Food Sciences and Nutrition. 2024; 75(3): 264–276; doi: 10.1080/09637486.2024.2303041.

64.   Cai T-T, Ye X-L, Li R-R, et al. Resveratrol Modulates the Gut Microbiota and Inflammation to Protect Against Diabetic Nephropathy in Mice. Front Pharmacol. 2020; 11: 1249; doi: 10.3389/fphar.2020.01249.

65.   Liu Y, Deng Y, Wang F, et al. A New Mechanism for Ginsenoside Rb1 to Promote Glucose Uptake, Regulating Riboflavin Metabolism and Redox Homeostasis. Metabolites 2022;12(11):1011; doi: 10.3390/metabo12111011.

66.   Yin J, Huang Y, Wang K, et al. Ginseng extract improves pancreatic islet injury and promotes β-cell regeneration in T2DM mice. Front Pharmacol. 2024; 15: 1407200; doi: 10.3389/fphar.2024.1407200.

67.   Delpino FM, Figueiredo LM. Resveratrol supplementation and type 2 diabetes: a systematic review and meta-analysis. Critical Reviews in Food Science and Nutrition. 2022; 62(16): 4465–4480; doi: 10.1080/10408398.2021.1875980.

68.   Zhu X, Wu C, Qiu S, et al. Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta-analysis. Nutr Metab (Lond). 2017; 14(1): 60; doi: 10.1186/s12986-017-0217-z.

69.   Wang L, Liu D, Wei G, et al. Berberine and Metformin in the Treatment of Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis of Randomized Clinical Trials. Health. 2021; 13(11): 1314–1329; doi: 10.4236/health.2021.1311096.

70.   Mazurek A, Pawlicki M, Stachyrak K, et al. Berberine in the treatment of type 2 diabetes - literature review. J Educ Health Sport. 2024; 67: 49000; doi: 10.12775/JEHS.2024.67.49000.

71.   Zuñiga LY, Aceves-de La Mora MCA, González-Ortiz M, et al. Effect of Chlorogenic Acid Administration on Glycemic Control, Insulin Secretion, and Insulin Sensitivity in Patients with Impaired Glucose Tolerance. Journal of Medicinal Food. 2018; 21(5): 469–473; doi: 10.1089/jmf.2017.0110.

72.   Rezaeiamiri E, Bahramsoltani R, Rahimi R. Plant-derived natural agents as dietary supplements for the regulation of glycosylated hemoglobin: A review of clinical trials. Clinical Nutrition. 2020; 39(2): 331–342; doi: 10.1016/j.clnu.2019.02.006.

73.   Kour G, Haq SA, Bajaj BK, et al. Phytochemical add-on therapy to DMARDs therapy in rheumatoid arthritis: In vitro and in vivo bases, clinical evidence and future trends. Pharmacological Research. 2021; 169: 105618; doi: 10.1016/j.phrs.2021.105618.

74.   Petracca M, Quarantelli M, Moccia M, et al. ProspeCtive study to evaluate efficacy, safety and tOlerability of dietary supplemeNT of Curcumin (BCM95) in subjects with Active relapsing MultIple Sclerosis treated with subcutaNeous Interferon beta 1a 44 mcg TIW (CONTAIN): A randomized, controlled trial. Multiple Sclerosis and Related Disorders. 2021; 56: 103274; doi: 10.1016/j.msard.2021.103274.

75.   Krueger E, Austin M, Ekpo I, et al. Screening Phytochemicals for Alternative Diabetes Treatments. The FASEB Journal. 2020; 34(S1): 1–1; doi: 10.1096/fasebj.2020.34.s1.05911.

76.   Prabhakar PK, Doble M. Synergistic effect of phytochemicals in combination with hypoglycemic drugs on glucose uptake in myotubes. Phytomedicine. 2009; 16(12): 1119–1126; doi: 10.1016/j.phymed.2009.05.021.

77.   Wiciński M, Erdmann J, Nowacka A, et al. Natural Phytochemicals as SIRT Activators—Focus on Potential Biochemical Mechanisms. Nutrients. 2023; 15(16): 3578; doi: 10.3390/nu15163578.

78.   Yang DK, Kang H-S. Anti-Diabetic Effect of Cotreatment with Quercetin and Resveratrol in Streptozotocin-Induced Diabetic Rats. Biomolecules & Therapeutics. 2018; 26(2): 130–138; doi: 10.4062/biomolther.2017.254.

79.   Singh VK, Arora D, Ansari MI, et al. Phytochemicals based chemopreventive and chemotherapeutic strategies and modern technologies to overcome limitations for better clinical applications. Phytotherapy Research. 2019; 33(12): 3064–3089; doi: 10.1002/ptr.6508.

80.   Dhami N, Mishra AD. Phytochemical variation: How to resolve the quality controversies of herbal medicinal products? Journal of Herbal Medicine. 2015; 5(2): 118–127; doi: 10.1016/j.hermed.2015.04.002.

81.   Zhou R, Zheng Y, An X, et al. Dosage Modification of Traditional Chinese Medicine Prescriptions: An Analysis of Two Randomized Controlled Trials. Front Pharmacol. 2021; 12: 732698; doi: 10.3389/fphar.2021.732698.

82.   Gupta RC, Chang D, Nammi S, et al. Interactions between antidiabetic drugs and herbs: an overview of mechanisms of action and clinical implications. Diabetol Metab Syndr. 2017; 9(1): 59; doi: 10.1186/s13098-017-0254-9.

83.   Dasram MH, Walker RB, Khamanga SM. Recent Advances in Endocannabinoid System Targeting for Improved Specificity: Strategic Approaches to Targeted Drug Delivery. IJMS. 2022; 23(21): 13223; doi: 10.3390/ijms232113223.

84.   McClements DJ. Advances in nanoparticle and microparticle delivery systems for increasing the dispersibility, stability, and bioactivity of phytochemicals. Biotechnology Advances. 2020; 38: 107287; doi: 10.1016/j.biotechadv.2018.08.004.

85.   Pache M, Bachhav G, Bhamare A, et al. Mapping Drug Responses Through Multi-Omics: A New Era of Bioinformatics in Precision Medicine. Int J Sci R Tech. 2025; 2(8): 319–335; doi: 10.5281/ZENODO.16914606.

86.   Manish Khairnar* SM. Integrative Multi-Omics in Precision Medicine: From Molecular Interconnectivity to Single-Cell Resolution. 2025; doi: 10.5281/ZENODO.15831126.

87.   Pache MM, Pangavhane RR, Nikam SV, et al. CRISPR-Cas9 in Pharmaceutical Research: Applications, Challenges, Ethical Considerations and Future Directions. Asian Journal of Pharmacy and Technology. 2025.

88.   Mechchate H, Es-safi I, Haddad H, et al. Combination of Catechin, Epicatechin, and Rutin: Optimization of a novel complete antidiabetic formulation using a mixture design approach. The Journal of Nutritional Biochemistry. 2021; 88: 108520; doi: 10.1016/j.jnutbio.2020.108520.

89.   Omale S, Amagon KI, Johnson TO, et al. A systematic analysis of anti-diabetic medicinal plants from cells to clinical trials. Peer J. 2023; 11: e14639; doi: 10.7717/peerj.14639.

 

Received on 27.07.2025      Revised on 11.09.2025 Accepted on 20.10.2025      Published on 31.01.2026 Available online from February 07, 2026 Res. J. Pharmacognosy and Phytochem. 2026; 18(1):38-48. DOI: 10.52711/0975-4385.2026.00007 ©A&V Publications All right reserved
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.